Marché du traitement du syndrome du côlon irritable – Analyse des tendances et de la croissance | Année de prévision 2031

  • Report Code : TIPRE00006814
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 180
Buy Now

Le marché du traitement du syndrome du côlon irritable (IBS) était évalué à 2 153,89 millions de dollars US en 2020 et devrait atteindre 4 600,30 millions de dollars US d'ici 2028 ; il devrait croître à un TCAC de 10,1 % de 2021 à 2028.



Les principaux facteurs tels que la prévalence croissante des maladies du syndrome du côlon irritable et l'augmentation des activités de recherche et développement stimulent la croissance du marché. Cependant, le nombre limité de produits disponibles et l'inefficacité du traitement freinent la croissance du marché. Le SCI est une maladie chronique courante qui affecte l'organe abdominal, le gros intestin. Il est également connu sous le nom de côlon spastique, de colite muqueuse, de côlon irritable et de colite spastique. La condition est très différente de la maladie inflammatoire de l'intestin. Il présente des symptômes tels que des crampes, des douleurs abdominales, des ballonnements, des gaz et de la diarrhée ou de la constipation, ou les deux à la fois. Si les symptômes sont légers, ils peuvent être gérés en modifiant le stress, le mode de vie et le régime alimentaire. D'autre part, les symptômes graves sont traités avec des médicaments et des conseils.



En APAC, de nombreuses mesures ont été mises en œuvre pour contenir la propagation du nouveau coronavirus qui cause le COVID-19. Les mesures ont perturbé les opérations de nombreuses entreprises dans divers secteurs, y compris le secteur de la santé. La quarantaine du personnel, les défaillances de la chaîne d'approvisionnement et les réductions de la demande ont généré de graves complications pour les entreprises. Par ailleurs, on note une baisse importante des soins hospitaliers et ambulatoires dans les chaînes hospitalières privées. Pour soulager les systèmes de santé, de nombreuses cliniques reportent les rendez-vous non critiques. Ce scénario entrave la croissance du traitement du syndrome du côlon irritable (IBS).



Régions lucratives pour le marché du traitement du syndrome du côlon irritable (IBS)




Aperçu du marché



Augmentation de la prévalence du syndrome du côlon irritable et des affections associées



Le syndrome du côlon irritable est une affection gastro-intestinale chronique principalement observée qui est causée par des troubles des habitudes intestinales et des douleurs abdominales . La maladie est également connue sous le nom de côlon spastique, côlon irritable, colite muqueuse et colite spastique. Le syndrome du côlon irritable présente des symptômes tels que douleurs abdominales, constipation, diarrhée et crampes. Les systèmes de santé des régions connaissent une croissance considérable de l'incidence du syndrome du côlon irritable. Une donnée publiée par la Fondation internationale pour les troubles gastro-intestinaux indique que parmi tous les patients atteints du SII, environ 40 % des patients ont un SII léger, environ 35 % ont un SII modéré et environ 25 % souffrent d'un SII grave. Beaucoup de gens ne reconnaissent pas les symptômes du SCI.



Certains facteurs tels que les allergies alimentaires, les stades de développement de la gastro-entérite, les mouvements sporadiques du côlon, la composition anormale de la sérotonine dans le côlon et la maladie coeliaque légère font partie des facteurs de risque pouvant causer le SII. Ces facteurs devraient accélérer le taux de prévalence du SII dans le monde. Par exemple, selon une étude publiée sur NCBI en 2018, on estime que le SCI affecte environ 10 à 16 % de la population américaine chaque année. Une telle prévalence stupéfiante de l'IBS est susceptible de stimuler le marché du traitement du syndrome du côlon irritable (IBS) au cours de la période de prévision.



Insights basés sur le type



En fonction du type, le marché du traitement du syndrome du côlon irritable (IBS) est segmenté en IBS mixte (IBS-M), IBS avec diarrhée (IBS-D) , et IBS avec constipation (IBS-C). En 2020, le segment IBS mixte (IBS-M) détenait la plus grande part du marché. En outre, le même segment devrait enregistrer le TCAC le plus élevé au cours de la période de prévision. La prévalence croissante du SCI chez les femmes et les hommes devrait stimuler la demande de médicaments capables de traiter les symptômes combinés de la constipation et de la diarrhée. La prévalence du SCI est plus élevée dans la population vieillissante. Par conséquent, la demande de médicaments pour traiter le SCI mixte est susceptible de croître de manière significative au cours de la période de prévision,



Marché du traitement du syndrome du côlon irritable (SCI), par type - 2020 et 2028



Informations sur les produits



En fonction des produits, le marché du traitement du syndrome du côlon irritable (IBS) est segmenté en rifaximine, eluxadoline, lubiprostone, linaclotide et autres. Le segment du linaclotide détenait la plus grande part du marché en 2020. De plus, on estime que le même segment enregistrera le TCAC le plus élevé du marché au cours de la période de prévision. La croissance du marché pour le segment est attribuée à des facteurs tels que la fabrication croissante de la version générique du linaclotide et la consolidation croissante du marché pour le développement et la commercialisation du linaclotide pour traiter le SII.



Distribution Channel-Based Insights



Sur la base du canal de distribution, le marché du traitement du syndrome du côlon irritable (IBS) est segmenté en pharmacies hospitalières, pharmacies et pharmacies de détail, et pharmacies en ligne. En 2020, le segment des pharmacies hospitalières détenait la plus grande part de marché. Cependant, le segment des pharmacies et des pharmacies de détail devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.



Perspectives stratégiques



Les entreprises opérant sur le marché du traitement du syndrome du côlon irritable (IBS) adoptent la stratégie d'innovations de produits pour répondre à l'évolution des demandes des clients à travers le monde, ce qui leur permet également de maintenir leur marque sur le marché mondial.



Marché du traitement du syndrome du côlon irritable (IBS) - par type




  • IBS avec diarrhée (IBS-D)

  • IBS avec constipation (IBS-C )

  • Mixed IBS (IBS-M)

Marché du traitement du syndrome du côlon irritable (IBS) – par produit




  • Rifaximine
  • Eluxadoline

  • Linaclotide

  • Lubiprostone

  • Autres

Marché du traitement du syndrome du côlon irritable (IBS) - par canal de distribution




  • Pharmacies hospitalières

  • Drogueries et pharmacies de détail

  • Pharmacies en ligne

Syndrome du côlon irritable (IBS) Marché du traitement – Par zone géographique




  • Amérique du Nord

    • États-Unis

    • Canada

    • Mexique

  • Europe

    • France

    • Allemagne

    • Italie

    • Royaume-Uni

    • Espagne
    • Reste de l'Europe


  • Asie-Pacifique (APAC)

    • Chine

    • Inde

    • Corée du Sud

    • Japon

    • Australie

    • Reste de l'APAC


  • Moyen-Orient et Afrique (MEA)

    • Afrique du Sud

    • Arabie saoudite

    • EAU

    • Reste de la MEA


  • Amérique du Sud et centrale (SCAM)

    • Brésil

    • Argentine

    • Reste de la SCAM


Profils d'entreprise




  • Ironwood Pharmaceuticals, Inc.

  • AbbVie.

  • Sebela Pharmaceuticals, Inc.

  • Takeda Pharmaceutical Company Limited

  • Alfasigma SpA

  • Astellas Pharma Inc.

  • AstraZeneca

  • Synthetic Biologics, Inc.

  • Bausch + Lomb Incorporée

  • Lannett Company Inc

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is irritable bowel syndrome (IBS) treatment?

Irritable bowel syndrome (IBS) is a common disorder that affects the abdominal organ, large intestine. It is also known as spastic colon, mucous colitis, irritable colon, and spastic colitis. The condition is much different than inflammatory bowel disease. However, it is a chronic condition which a person must manage for a longer period. It shows symptoms such as cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both at the same. These symptoms can be managed by changing stress, lifestyle, and diet. And the more severe symptoms are treated with medication and counseling.

What are the driving factors for the irritable bowel syndrome (IBS) treatment market across the globe?

The factors that are driving growth of the market are increasing prevalence of irritable bowel syndrome diseases and increasing research & development activities.

Who are the major players in the irritable bowel syndrome (IBS) treatment market?

The irritable bowel syndrome (IBS) treatment market majorly consists of the players such as Ironwood Pharmaceuticals, Inc., AbbVie., Sebela Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Alfasigma S.p.A., Astellas Pharma Inc., AstraZeneca, Synthetic Biologics, Inc., Bausch + Lomb Incorporated and Lannett Company Inc amongst others.

The List of Companies - Irritable Bowel Syndrome (IBS) Treatment Market

  1. Ironwood Pharmaceuticals, Inc.
  2. AbbVie.
  3. Sebela Pharmaceuticals, Inc.
  4. Takeda Pharmaceutical Company Limited
  5. Alfasigma S.p.A.
  6. Astellas Pharma Inc.
  7. AstraZeneca
  8. Synthetic Biologics, Inc.
  9. Bausch + Lomb Incorporated
  10. Lannett Company Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports